Q2 FY25 Total Income was at Rs. 85.4 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
This product will be manufactured at Lupin’s Nagpur facility in India
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
The company uses iPS cells to develop treatments for diseases relating to the kidney
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Subscribe To Our Newsletter & Stay Updated